Top ▲

amyloid P component, serum

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 2839

Nomenclature: amyloid P component, serum

Family: Serum pentraxins

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 223 1q23.2 APCS amyloid P component, serum 3-4
Mouse - 224 1 80.33 cM Apcs amyloid P component, serum
Rat - 228 13q24 Apcs amyloid P component, serum
Gene and Protein Information Comments
The human protein has a signal peptide (1-19) with a mature peptide chain of 204 amino acids (20-223).
Previous and Unofficial Names Click here for help
serum amyloid P-component | amyloid P component | pentraxin-2 | pentraxin 2 | PTX2 | SAP
Database Links Click here for help
Alphafold
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
CPHPC Small molecule or natural product Primary target of this compound Ligand has a PDB structure Hs Binding 6.1 pIC50 7
pIC50 6.1 (IC50 9x10-7 M) [7]
Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
dezamizumab Peptide Primary target of this compound Hs Binding - - 1
[1]
Immunopharmacology Comments
Serum amyloid P or pentraxin 2 is a multi-function circulating plasma protein. It exhibits activity as a soluble pattern recognition receptor of the innate immune system, that can bind DNA and histones when these are released from damaged cells.

A recombinant form of human pentraxin 2 (PRM-151; Promedior) has been reported as an anti-fibrotic immunomodulator [2]. PRM-151 was found to inhibit the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages, with an associated anti-fibrotic effect in a preclinical model of opacity-producing corneal injury [6]. In humans PRM-151 has demonstrated clinical utility in patents with idiopathic pulmonary fibrosis (IPF; see Phase 2 trial NCT02550873) [5]. The anti-fibrotic efficacy of PRM-151 is also being evaluated in patients with myelofibrosis, and as a mechanism to reduce scarring post-trabeculectomy in gluacoma patients. Click here to link to ClinicalTrials.gov's full list of PRM-151 studies.
Immuno Process Associations
Immuno Process:  Barrier integrity
GO Annotations:  Associated to 1 GO processes
GO:0046597 negative regulation of viral entry into host cell IDA
Immuno Process:  Inflammation
GO Annotations:  Associated to 3 GO processes
GO:0002674 negative regulation of acute inflammatory response IC
GO:0006953 acute-phase response TAS
GO:0045087 innate immune response IDA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 3 GO processes
GO:0002674 negative regulation of acute inflammatory response IC
GO:0006958 complement activation, classical pathway IBA
GO:0045656 negative regulation of monocyte differentiation IDA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes
GO:0045656 negative regulation of monocyte differentiation IDA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 1 GO processes
GO:0006958 complement activation, classical pathway IBA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 1 GO processes
GO:0006958 complement activation, classical pathway IBA

References

Show »

1. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468 (7320): 93-7. [PMID:20962779]

2. Duffield JS, Lupher Jr ML. (2010) PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect, 23 (5): 305-15. [PMID:20603654]

3. Mantzouranis EC, Dowton SB, Whitehead AS, Edge MD, Bruns GA, Colten HR. (1985) Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1. J Biol Chem, 260 (12): 7752-6. [PMID:2987268]

4. Ohnishi S, Maeda S, Shimada K, Arao T. (1986) Isolation and characterization of the complete complementary and genomic DNA sequences of human serum amyloid P component. J Biochem, 100 (4): 849-58. [PMID:3029048]

5. Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE et al.. (2019) Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med, 7 (8): 657-664. [PMID:31122893]

6. Santhiago MR, Singh V, Barbosa FL, Agrawal V, Wilson SE. (2011) Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits. Exp Eye Res, 93 (5): 786-9. [PMID:21933674]

7. Wermuth CG. (2004) Selective optimization of side activities: another way for drug discovery. J Med Chem, 47 (6): 1303-14. [PMID:14998318]

How to cite this page

Serum pentraxins: amyloid P component, serum. Last modified on 11/02/2020. Accessed on 18/09/2021. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2839.